Fanconi anaemia, BRCA2 and familial considerations - Follow up on a previous case report

Acta Paediatrica, International Journal of Paediatrics

Volumn 99, Issue 11, 2010, Pages 1741-1743

  Bodd, Trine Levin ^a   Van Ghelue, Marijke ^b   Eiklid, Kristin ^c   Ruud, Ellen ^d   Møller, Pål ^a   Mæhle, Lovise ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN;

ARTICLE; BREAST CANCER; FAMILY HISTORY; FANCONI ANEMIA; FOLLOW UP; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; HUMAN; MEDICAL RESEARCH; MEDULLOBLASTOMA; MISSENSE MUTATION; OVARY CANCER; PRIORITY JOURNAL; ADULT; AGED; BREAST TUMOR; FEMALE; GENETICS; HETEROZYGOTE; MALE; MUTATION; OVARY TUMOR; PEDIGREE; PRESCHOOL CHILD; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BREAST NEOPLASMS; CHILD, PRESCHOOL; FANCONI ANEMIA; FEMALE; FOLLOW-UP STUDIES; GENES, BRCA2; HETEROZYGOTE; HUMANS; MALE; MUTATION; OVARIAN NEOPLASMS; PEDIGREE;

EID: 84988290452     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2010.01929.x     Document Type: Article

References (8)

1. Ruud E, Wesenberg F. Microcephalus, medulloblastoma and excessive toxicity from chemotherapy: An unusual presentation of Fanconi anemia. Acta Paediatr 2001; 90: 580-3.
2. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, de Die- Smulders C, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002; 297: 606-9.
3. Online Mendelian Inheritance in Man (OMIM). Available at: Http://www.ncbi.nlm.nih.gov/Omim/.
4. Wagner JE, Tolar J, Levran O, Scholl T, Deffenbaugh A, Satagopan J, et al. Germline mutations in BRCA2: Shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia. Blood 2004; 103: 3226-9.
5. The Breast Cancer Linkage Consortium (BIC). Available at: Http://research.nhgri.nih.gov/bic/.
6. Karchin R, Agarwal M, Sali A, Couch F, Beattie MS. Classifying variants of undetermined significance in BRCA2 with protein likelihood ratios. Cancer Inform 2008; 6: 203-16.
7. Alter BP, Rosenberg PS, Brody LC. Clinical and molecular features associated with biallelic mutations in FANCD1/ BRCA2. J Med Genet 2007; 44: 1-9.
8. Møller P, Hagen AI, Apold J, Mæhle L, Clark N, Fiane B, et al. Genetic epidemiology of BRCA mutations-family history detects less than 50% of the mutation carriers. Eur J Cancer 2007; 43: 1713-7.